Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Metabolomics Provides a New Approach to Kidney Cancer Diagnosis

By LabMedica International staff writers
Posted on 20 Sep 2011
Metabolomics techniques identified metabolites in the urine of patients with kidney cancer. More...


Often diagnosed at late stages, treatment options for kidney cancer become severely limited: greater understanding of tumor metabolism leading ultimately to novel approaches to early diagnosis is needed.

Two studies support the use of metabolomics in the diagnosis and treatment of kidney cancer. In the first study, scientists identified metabolites in the urine of patients with kidney cancer (renal cell carcinoma, RCC) that appear at different levels compared with patients without kidney cancer. The levels of quinolinate, 4-hydroxybenzoate, and gentisate, metabolites involved in common biochemical pathways of specific amino acid and energy metabolism, were significantly different in urine from RCC patients.

This result is consistent with protein breakdown and utilization as well as the Warburg effect in kidney cancer tumors. The investigators also showed that addition of quinolinate, or α-ketoglutarate, which increased significantly in kidney cancer, stimulated growth in RCC cell lines more than addition of gentisate. This study was published in the May 10, 2011 edition of OMICS, A Journal of Integrative Biology.

The second study compared urine samples from patients with and without kidney cancer, using metabolomics. The study found increases in urinary acyl-carnitines in patients with kidney cancer, with the highest levels associated with high cancer grades. The study was published online in July 2011 the International Journal of Cancer.

The studies were conducted by Robert Weiss, MD of the Cancer Center at the University of California Davis (Sacramento, CA, USA) and colleagues at the University’s Departments of Public Health Sciences and Internal Medicine in collaboration with Metabolon (Durham, NC, USA) scientists.

According to Dr. Weiss, "Currently there are no useful biofluid markers for this disease, so diagnosis is dependent on imaging techniques that are not generally used for screening. Further evaluation of metabolomics analysis, as well as confirmation of the specific potential biomarkers using a larger cohort will lead to new avenues of kidney cancer diagnosis and therapy."

Related Links:
Cancer Center at the University of California Davis
Metabolon


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
Gold Member
Serum Indices Control
Acusera Serum Indices Control
Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: A new study links broad genomic sequencing before first-line therapy to longer survival, supporting its role in treatment decisions (Image Credit: Shutterstock)

Study Supports Broad Genomic Profiling Before First-Line Lung Cancer Treatment

Biomarker testing plays a critical role in advanced non-small cell lung cancer by identifying patients who may benefit from targeted therapies. However, testing only one or two genes can miss actionable... Read more

Immunology

view channel
Image: The findings underscore the importance of aligning allergy testing with clinical history and diagnostic guidelines to reduce inappropriate testing and its consequences (Image Credit: iStock)

Survey Finds Gap Between Food Allergy Testing Awareness and Clinical Practice

Food allergy evaluation can be challenging when laboratory results do not match clinical symptoms. Broad food allergy panels may detect sensitization without confirming an actual allergy, potentially leading... Read more

Industry

view channel
Image Credit: iStock

C2N Makes PrecivityAD2 Alzheimer’s Blood Test Available to Clinicians

Diagnosing Alzheimer’s disease can be challenging, particularly in patients with mild cognitive impairment or early dementia. Assessing brain amyloid pathology can guide clinical decisions, but diagnostic... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.